FRM
BLCM

Fox Run Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Fox Run Management’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,810
Closed -$328K – 927
2017
Q2 		$328K Buy
2,810
+1,427
+103% +$177K 0.11% 376
2017
Q1 		$171K Buy
+1,383
New +$181K 0.07% 507

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fox Run Management's BLCM Position: Q3 2017 in Review

Fox Run Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2017, closing a stake of 2,810 shares — an estimated $328K sold.

Fox Run Management first reported a position in BLCM in Q1 2017 and held it in 2 quarters. The position peaked at $328K in Q2 2017. 88 funds tracked by Wall St. Rank hold BLCM as of Q3 2017.

  • Fox Run Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Fox Run Management sold 2,810 Bellicum Pharmaceuticals, Inc. shares in Q3 2017, an estimated $328K.
  • Fox Run Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2017 and held it in 2 quarters.
  • Fox Run Management's Bellicum Pharmaceuticals, Inc. position peaked at $328K in Q2 2017.
  • 88 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2017.

Based on Fox Run Management's 13F filing for Q3 2017, filed 23 Oct 2017.